Upfront Briefing
Hansa Biopharma put a hard circle on the calendar: the FDA set a Dec. 19, 2026 PDUFA action date for its imlifidase BLA.
On the capital-and-numbers side, MAIA closed a $30M underwritten public offering, while BillionToOne’s update offered another read-through on scaled diagnostics momentum — handy inputs for anyone trying to keep a model honest.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,869.5 |
+0.8% |
+0.4% |
| Nasdaq 100 |
25,093.68 |
+1.5% |
(0.6%) |
| Russell 2000 |
2,636.0 |
+1.1% |
+6.2% |
| Healthcare (XLV) |
157.05 |
+0.2% |
+1.5% |
| Biotech (XBI) |
126.42 |
+2.4% |
+3.7% |
| Nasdaq Biotech (NBI) |
5,967.28 |
+1.6% |
+4.6% |
| Clinical Trials (BBC) |
42.5 |
+3.2% |
+10.3% |
|
-
Risk-on rebound: equities clawed back losses as oil stopped accelerating and the market priced a lower near-term “war premium” — helping duration and growth outperform.
-
Biotech beta expressed on the upside: XBI +2.4% outpaced the S&P 500 +0.8% as higher-vol, catalyst-driven names caught the bid in a broader risk reset.
-
Market data: U.S. cash close Wed 04-Mar-2026.
The Big 3
|
1
|
MAIA Biotechnology closes $30M underwritten public offering
|
- MAIA Biotechnology closed an underwritten offering of 20,000,000 shares at $1.50/sh for $30M gross proceeds (before fees/expenses).
-
Why it matters:
This is classic microcap “runway financing”: the deal buys time into near-term catalysts, but the size (20M shares) also creates real dilution + potential trading overhang. Practically, the $1.50 print becomes a near-term valuation anchor — if execution is clean, it can rebase the stock; if not, it can compress optionality and raise the bar for the next raise.
- Source: GlobeNewswire
|
|
2
|
FDA leadership changes announced, including top operating official retirement
|
-
The FDA’s top operations official will retire, with a long-tenured deputy set to take over in April, against a backdrop of continued scrutiny around senior leadership in biologics oversight.
-
Why it matters:
For biotech investors, leadership churn is about variance: it can widen the distribution on review timing, meeting access, and how aggressively FDA leans into class-wide safety/CMC questions. That flows directly into probability-weighted NPVs — especially for near-term catalysts where a 1–2 quarter slip, an unexpected information request, or a narrower label can move the stock more than the data itself.
-
Source:
Endpoints
-
More:
BioCentury
|
| 3 | Hansa Biopharma imlifidase BLA gets Dec. 19, 2026 PDUFA |
-
Hansa Biopharma said the FDA set a Dec. 19, 2026 PDUFA action date for its imlifidase BLA; if approved, it would be the first treatment aimed at highly sensitized kidney-transplant candidates.
-
Why it matters:
A dated PDUFA turns regulatory risk into a time-bound catalyst: it tightens the financing calendar, improves planning certainty (CMC, launch prep, post-marketing commitments), and reduces “acceptance ambiguity” now that the clock is running. For investors, the debate shifts from “will it file/when” to probability-weighting label, transplant center adoption, and commercial execution in a niche but high-value workflow.
-
Source:
Hansa Biopharma
|
Everything Else that broke
- Sanofi board proposes Christel Heydemann as director. — PR
-
BillionToOne reports Q4/FY25 results and updates 2026 outlook. — PR
- Bourla comments add to cloud over Prasad, per BioCentury. — BioCentury
- BioCentury: February FDA approvals include second CNPV. — BioCentury
- NEJM publishes first data suggesting potential disease modification in Dravet syndrome (zorevunersen), per a company release. — PR
- Akeso cites long-term Phase 2 cadonilimab data in R/M cervical cancer. — PR
- Bioxytran reports dose optimization, says it’s advancing toward a Phase 3 registrational trial for ProLectin-M. — PR
- BioCentury: uniQure drops $1B after FDA rejection; Aavark falls on a cardiac safety signal. — BioCentury
- BD gets EU CE Mark for Revello covered stent in iliac arteries. — PR
- BioCentury: single-cell atlases point to druggable nodes in Down syndrome. — BioCentury
- Galapagos gets transparency notifications from Bank of America. — PR
- Syndax reports inducement grants under Nasdaq Listing Rule 5635(c)(4). — PR
- Yale’s Craig Crews builds a model to guide startups out of academia’s “valley of death,” per Endpoints. — Endpoints
- SciBase cites a publication on real-world Nevisense experience improving melanoma detection. — PR
- BioVersys sets full-year 2025 results date and business update call. — PR
- BioSpace: many would return to companies that laid them off. — BioSpace
- Aquestive reports Q4/FY 2025 results and provides a business update. — PR
- ImmuCell posts unaudited FY 2025 financial results. — PR
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
-
Sectra acquires Oxipit to push autonomous imaging AI. — PR
-
Esperion to acquire Corstasis for $75M upfront plus up to $180M in milestones (and royalties), adding Enbumyst (bumetanide nasal spray) to its cardiovascular franchise. —
PR
VC / Private Financings
-
Angitia raises $130M Series D to advance its bone disease pipeline.
Syndicate: lead not disclosed; investors included Frazier Life Sciences, Venrock Healthcare Capital Partners, RA Capital Management, and Wellington Management. —
Fierce Biotech
-
Antiverse raises $9.3M Series A to advance AI-designed antibody programs and announces a research agreement with the Cystic Fibrosis Foundation.
Syndicate: led by Soulmates Ventures; joined by Innovation Investment Capital, DOMiNO Ventures, and existing investors (DBW / Kadmos / i&i Biotech Fund). —
PR
-
Slate Medicines launches with $130M Series A to advance anti-PACAP therapies for migraine/headache disorders.
Syndicate: co-led by RA Capital, Forbion, and Foresite; joined by an undisclosed biotech investor. —
PR
IPOs / Follow-Ons
-
MAIA Biotechnology closes $30M underwritten public offering. —
PR
Academic Corner - Finerenone shows positive Phase 3 FINE-ONE results in CKD associated with type 1 diabetes. — Breakthrough T1D
|
